Fatigue in immune thrombocytopenia

British Journal of Haematology

Volumn 170, Issue 2, 2015, Pages 141-149

  Hill, Quentin A ^a   Newland, Adrian C ^b  

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^b ROYAL LONDON HOSPITAL   (United Kingdom)

Author keywords

Aetiology; Fatigue; Immune thrombocytopenia; Inflammation; Quality of life

Indexed keywords

IMMUNOSUPPRESSIVE AGENT;

COMPLICATION; FATIGUE; HUMAN; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; QUALITY OF LIFE;

FATIGUE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; QUALITY OF LIFE;

EID: 84934276567     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.13385     Document Type: Review

References (92)

1. Adelman, J.S. & Martin, L.B. (2009) Vertebrate sickness behaviors: adaptive and integrated neuroendocrine immune responses. Integrative and Comparative Biology, 49, 202-214.
2. Aledort, L.M., Hayward, C.P., Chen, M.G., Nichol, J.L. & Bussel, J. (2004) Prospective screening of 205 patients with ITP, including diagnosis, serological markers, and the relationship between platelet counts, endogenous thrombopoietin, and circulating antithrombopoietin antibodies. American Journal of Hematology, 76, 205-213.
3. Alvarez Roman, M.T., Fernandez Bello, I., Arias-Salgado, E.G., Rivas Pollmar, M.I., Jimenez Yuste, V., Martin Salces, M. & Butta, N.V. (2014) Effects of thrombopoietin receptor agonists on procoagulant state in patients with immune thrombocytopenia. Thrombosis and Haemostasis, 112, 65-72.
4. Anderson, G., Berk, M. & Maes, M. (2014) Biological phenotypes underpin the physio-somatic symptoms of somatization, depression, and chronic fatigue syndrome. Acta Psychiatrica Scandinavica, 129, 83-97.
5. Arnold, D.M., Heddle, N.M., Carruthers, J., Cook, D.J., Crowther, M.A., Meyer, R.M., Liu, Y., Cook, R.J., McLeod, A., MacEachern, J.A., Mangel, J., Anderson, D., Vickars, L., Tinmouth, A., Schuh, A.C. & Kelton, J.G. (2012) A pilot randomized trial of adjuvant rituximab or placebo for nonsplenectomized patients with immune thrombocytopenia. Blood, 119, 1356-1362.
6. Barsevick, A.M., Cleeland, C.S., Manning, D.C., O'Mara, A.M., Reeve, B.B., Scott, J.A. & Sloan, J.A. (2010) ASCPRO recommendations for the assessment of fatigue as an outcome in clinical trials. Journal of Pain and Symptom Management, 39, 1086-1099.
7. Berti, D., Moons, P., Dobbels, F., Deuson, R., Janssens, A. & De, G.S. (2008) Impact of corticosteroid-related symptoms in patients with immune thrombocytopenic purpura: results of a survey of 985 patients. Clinical Therapeutics, 30, 1540-1552.
8. Blatt, J., Weston, B. & Gold, S. (2010) Fatigue as marker of thrombocytopenia in childhood idiopathic thrombocytopenic purpura. Pediatric Hematology and Oncology, 27, 65-67.
9. Bower, J.E. (2012) Fatigue, brain, behavior, and immunity: summary of the 2012 Named Series on fatigue. Brain, Behavior, and Immunity, 26, 1220-1223.
10. Bower, J.E. & Lamkin, D.M. (2013) Inflammation and cancer-related fatigue: mechanisms, contributing factors, and treatment implications. Brain, Behavior, and Immunity, 30, S48-S57.
11. Brenu, E.W., Van Driel, M.L., Staines, D.R., Ashton, K.J., Ramos, S.B., Keane, J., Klimas, N.G. & Marshall-Gradisnik, S.M. (2011) Immunological abnormalities as potential biomarkers in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis. Journal of Translational Medicine, 9, 81.
12. Broderick, G., Fuite, J., Kreitz, A., Vernon, S.D., Klimas, N. & Fletcher, M.A. (2010) A formal analysis of cytokine networks in chronic fatigue syndrome. Brain, Behavior, and Immunity, 24, 1209-1217.
13. Capuron, L., Pagnoni, G., Demetrashvili, M.F., Lawson, D.H., Fornwalt, F.B., Woolwine, B., Berns, G.S., Nemeroff, C.B. & Miller, A.H. (2007) Basal ganglia hypermetabolism and symptoms of fatigue during interferon-alpha therapy. Neuropsychopharmacology, 32, 2384-2392.
14. Catani, L., Sollazzo, D., Trabanelli, S., Curti, A., Evangelisti, C., Polverelli, N., Palandri, F., Baccarani, M., Vianelli, N. & Lemoli, R.M. (2013) Decreased expression of indoleamine 2, 3-dioxygenase 1 in dendritic cells contributes to impaired regulatory T cell development in immune thrombocytopenia. Annals of Hematology, 92, 67-78.
15. Cauch-Dudek, K., Abbey, S., Stewart, D.E. & Heathcote, E.J. (1998) Fatigue in primary biliary cirrhosis. Gut, 43, 705-710.
16. Cheng, G., Saleh, M.N., Marcher, C., Vasey, S., Mayer, B., Aivado, M., Arning, M., Stone, N.L. & Bussel, J.B. (2011) Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study. Lancet, 377, 393-402.
17. Cines, D.B. & Bussel, J.B. (2005) How I treat idiopathic thrombocytopenic purpura (ITP). Blood, 106, 2244-2251.
18. Clauw, D.J. (2014) Fibromyalgia: a clinical review. JAMA, 311, 1547-1555.
19. Cohen, Y.C., Djulbegovic, B., Shamai-Lubovitz, O. & Mozes, B. (2000) The bleeding risk and natural history of idiopathic thrombocytopenic purpura in patients with persistent low platelet counts. Archives of Internal Medicine, 160, 1630-1638.
20. Cooper, N. & Bussel, J. (2006) The pathogenesis of immune thrombocytopenic purpura. British Journal of Haematology, 133, 364-374.
21. Cuker, A. (2010) Toxicities of the thrombopoietic growth factors. Seminars in Hematology, 47, 289-298.
22. Culic, S., Salamunic, I., Konjevoda, P., Dajak, S. & Pavelic, J. (2013) Immune thrombocytopenia: serum cytokine levels in children and adults. Medical Science Monitor, 19, 797-801.
23. Del Vecchio, G.C., Giordano, P., Tesse, R., Piacente, L., Altomare, M. & De, M.D. (2012) Clinical significance of serum cytokine levels and thrombopoietic markers in childhood idiopathic thrombocytopenic purpura. Blood Transfusion, 10, 194-199.
24. Dittner, A.J., Wessely, S.C. & Brown, R.G. (2004) The assessment of fatigue: a practical guide for clinicians and researchers. Journal of Psychosomatic Research, 56, 157-170.
25. Dunn, A.J. (2006) Effects of cytokines and infections on brain neurochemistry. Clinical Neuroscience Research, 6, 52-68.
26. Emilia, G., Morselli, M., Luppi, M., Longo, G., Marasca, R., Gandini, G., Ferrara, L., D'Apollo, N., Potenza, L., Bertesi, M. & Torelli, G. (2002) Long-term salvage therapy with cyclosporin A in refractory idiopathic thrombocytopenic purpura. Blood, 99, 1482-1485.
27. Felger, J.C. & Miller, A.H. (2012) Cytokine effects on the basal ganglia and dopamine function: the subcortical source of inflammatory malaise. Frontiers in Neuroendocrinology, 33, 315-327.
28. Gabbay, V., Liebes, L., Katz, Y., Liu, S., Mendoza, S., Babb, J.S., Klein, R.G. & Gonen, O. (2010) The kynurenine pathway in adolescent depression: preliminary findings from a proton MR spectroscopy study. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 34, 37-44.
29. George, J.N., Mathias, S.D., Go, R.S., Guo, M., Henry, D.H., Lyons, R., Redner, R.L., Rice, L. & Schipperus, M.R. (2009) Improved quality of life for romiplostim-treated patients with chronic immune thrombocytopenic purpura: results from two randomized, placebo-controlled trials. British Journal of Haematology, 144, 409-415.
30. Gernsheimer, T. (2008) Epidemiology and pathophysiology of immune thrombocytopenic purpura. European Journal of Haematology. Supplementum, 69, 3-8.
31. Giannouli, S., Voulgarelis, M., Ziakas, P.D. & Tzioufas, A.G. (2006) Anaemia in systemic lupus erythematosus: from pathophysiology to clinical assessment. Annals of the Rheumatic Diseases, 65, 144-148.
32. Gudbrandsdottir, S., Birgens, H.S., Frederiksen, H., Jensen, B.A., Jensen, M.K., Kjeldsen, L., Klausen, T.W., Larsen, H., Mourits-Andersen, H.T., Nielsen, C.H., Nielsen, O.J., Plesner, T., Pulczynski, S., Rasmussen, I.H., Ronnov-Jessen, D. & Hasselbalch, H.C. (2013) Rituximab and dexamethasone vs dexamethasone monotherapy in newly diagnosed patients with primary immune thrombocytopenia. Blood, 121, 1976-1981.
33. Hewlett, S., Chalder, T., Choy, E., Cramp, F., Davis, B., Dures, E., Nicholls, C. & Kirwan, J. (2011) Fatigue in rheumatoid arthritis: time for a conceptual model. Rheumatology (Oxford), 50, 1004-1006.
34. Huyser, B.A., Parker, J.C., Thoreson, R., Smarr, K.L., Johnson, J.C. & Hoffman, R. (1998) Predictors of subjective fatigue among individuals with rheumatoid arthritis. Arthritis and Rheumatism, 41, 2230-2237.
35. Ifuku, M., Hossain, S.M., Noda, M. & Katafuchi, T. (2014) Induction of interleukin-1beta by activated microglia is a prerequisite for immunologically induced fatigue. European Journal of Neuroscience, 40, 3253-3263.
36. Jacobsen, P.B., Donovan, K.A., Trask, P.C., Fleishman, S.B., Zabora, J., Baker, F. & Holland, J.C. (2005) Screening for psychologic distress in ambulatory cancer patients. Cancer, 103, 1494-1502.
37. Joyce, J., Hotopf, M. & Wessely, S. (1997) The prognosis of chronic fatigue and chronic fatigue syndrome: a systematic review. QJM, 90, 223-233.
38. Kamath, J., Yarbrough, G.G., Prange, Jr, A.J. & Winokur, A. (2009) The thyrotropin-releasing hormone (TRH)-immune system homeostatic hypothesis. Pharmacology & Therapeutics, 121, 20-28.
39. Kappers-Klunne, M.C. & van't Veer, M.B. (2001) Cyclosporin A for the treatment of patients with chronic idiopathic thrombocytopenic purpura refractory to corticosteroids or splenectomy. British Journal of Haematology, 114, 121-125.
40. Koornstra, R.H., Peters, M., Donofrio, S., van den Borne, B. & de Jong, F.A. (2014) Management of fatigue in patients with cancer - a practical overview. Cancer Treatment Reviews, 40, 791-799.
41. Krayenbuehl, P.A., Battegay, E., Breymann, C., Furrer, J. & Schulthess, G. (2011) Intravenous iron for the treatment of fatigue in nonanemic, premenopausal women with low serum ferritin concentration. Blood, 118, 3222-3227.
42. Kuter, D.J., Rummel, M., Boccia, R., Macik, B.G., Pabinger, I., Selleslag, D., Rodeghiero, F., Chong, B.H., Wang, X. & Berger, D.P. (2010) Romiplostim or standard of care in patients with immune thrombocytopenia. New England Journal of Medicine, 363, 1889-1899.
43. Kuter, D.J., Mathias, S.D., Rummel, M., Mandanas, R., Giagounidis, A.A., Wang, X. & Deuson, R.R. (2012) Health-related quality of life in nonsplenectomized immune thrombocytopenia patients receiving romiplostim or medical standard of care. American Journal of Hematology, 87, 558-561.
44. Kwidzinski, E. & Bechmann, I. (2007) IDO expression in the brain: a double-edged sword. Journal of Molecular Medicine (Berlin), 85, 1351-1359.
45. Lasselin, J., Laye, S., Dexpert, S., Aubert, A., Gonzalez, C., Gin, H. & Capuron, L. (2012) Fatigue symptoms relate to systemic inflammation in patients with type 2 diabetes. Brain, Behavior, and Immunity, 26, 1211-1219.
46. Lee, T.W., Iser, J.H., Sparrow, M.P., Newnham, E.D., Headon, B.J. & Gibson, P.R. (2009) Thiopurines, a previously unrecognised cause for fatigue in patients with inflammatory bowel disease. Journal of Crohn's and Colitis, 3, 196-199.
47. Lewis, G. & Wessely, S. (1992) The epidemiology of fatigue: more questions than answers. Journal of Epidemiology and Community Health, 46, 92-97.
48. Ma, D., Zhu, X., Zhao, P., Zhao, C., Li, X., Zhu, Y., Li, L., Sun, J., Peng, J., Ji, C. & Hou, M. (2008) Profile of Th17 cytokines (IL-17, TGF-beta, IL-6) and Th1 cytokine (IFN-gamma) in patients with immune thrombocytopenic purpura. Annals of Hematology, 87, 899-904.
49. Mathias, S.D., Bussel, J.B., George, J.N., McMillan, R., Okano, G.J. & Nichol, J.L. (2007) A disease-specific measure of health-related quality of life for use in adults with immune thrombocytopenic purpura: its development and validation. Health and Quality of Life Outcomes, 5, 11.
50. Mathias, S.D., Gao, S.K., Miller, K.L., Cella, D., Snyder, C., Turner, R., Wu, A., Bussel, J.B., George, J.N., McMillan, R., Wysocki, D.K. & Nichol, J.L. (2008) Impact of chronic Immune Thrombocytopenic Purpura (ITP) on health-related quality of life: a conceptual model starting with the patient perspective. Health and Quality of Life Outcomes, 6, 13.
51. McMillan, R., Bussel, J.B., George, J.N., Lalla, D. & Nichol, J.L. (2008) Self-reported health-related quality of life in adults with chronic immune thrombocytopenic purpura. American Journal of Hematology, 83, 150-154.
52. Miller, A.H., Ancoli-Israel, S., Bower, J.E., Capuron, L. & Irwin, M.R. (2008) Neuroendocrine-immune mechanisms of behavioral comorbidities in patients with cancer. Journal of Clinical Oncology, 26, 971-982.
53. Monk, J.P., Phillips, G., Waite, R., Kuhn, J., Schaaf, L.J., Otterson, G.A., Guttridge, D., Rhoades, C., Shah, M., Criswell, T., Caligiuri, M.A. & Villalona-Calero, M.A. (2006) Assessment of tumor necrosis factor alpha blockade as an intervention to improve tolerability of dose-intensive chemotherapy in cancer patients. Journal of Clinical Oncology, 24, 1852-1859.
54. Newton, J.L., Reese, J.A., Watson, S.I., Vesely, S.K., Bolton-Maggs, P.H., George, J.N. & Terrell, D.R. (2011) Fatigue in adult patients with primary immune thrombocytopenia. European Journal of Haematology, 86, 420-429.
55. Nikolaus, S., Bode, C., Taal, E. & van de Laar, M.A. (2013) Fatigue and factors related to fatigue in rheumatoid arthritis: a systematic review. Arthritis Care & Research, 65, 1128-1146.
56. Olsson, B., Andersson, P.O., Jernas, M., Jacobsson, S., Carlsson, B., Carlsson, L.M. & Wadenvik, H. (2003) T-cell-mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura. Nature Medicine, 9, 1123-1124.
57. Panitsas, F.P., Theodoropoulou, M., Kouraklis, A., Karakantza, M., Theodorou, G.L., Zoumbos, N.C., Maniatis, A. & Mouzaki, A. (2004) Adult chronic idiopathic thrombocytopenic purpura (ITP) is the manifestation of a type-1 polarized immune response. Blood, 103, 2645-2647.
58. Pardini, M., Cordano, C., Benassi, F., Mattei, C., Sassos, D., Guida, S., Serrati, C., Primavera, A., Amore, M., Cocito, L. & Emberti, G.L. (2014) Agomelatine but not melatonin improves fatigue perception: a longitudinal proof-of-concept study. European Neuropsychopharmacology, 24, 939-944.
59. Peerschke, E.I., Andemariam, B., Yin, W. & Bussel, J.B. (2010) Complement activation on platelets correlates with a decrease in circulating immature platelets in patients with immune thrombocytopenic purpura. British Journal of Haematology, 148, 638-645.
60. Pesmatzoglou, M., Lourou, M., Goulielmos, G.N. & Stiakaki, E. (2012) DNA methyltransferase 3B gene promoter and interleukin-1 receptor antagonist polymorphisms in childhood immune thrombocytopenia. Clinical & Developmental Immunology, 2012, 352059.
61. Peuckmann-Post, V., Elsner, F., Krumm, N., Trottenberg, P. & Radbruch, L. (2010) Pharmacological treatments for fatigue associated with palliative care. Cochrane Database Systematic Review, Issue 11, CD006788.
62. Provan, D., Stasi, R., Newland, A.C., Blanchette, V.S., Bolton-Maggs, P., Bussel, J.B., Chong, B.H., Cines, D.B., Gernsheimer, T.B., Godeau, B., Grainger, J., Greer, I., Hunt, B.J., Imbach, P.A., Lyons, G., McMillan, R., Rodeghiero, F., Sanz, M.A., Tarantino, M., Watson, S., Young, J. & Kuter, D.J. (2010) International consensus report on the investigation and management of primary immune thrombocytopenia. Blood, 115, 168-186.
63. Ricci, J.A., Chee, E., Lorandeau, A.L. & Berger, J. (2007) Fatigue in the U.S. workforce: prevalence and implications for lost productive work time. Journal of Occupational and Environmental Medicine, 49, 1-10.
64. Riemsma, R.P., Rasker, J.J., Taal, E., Griep, E.N., Wouters, J.M. & Wiegman, O. (1998) Fatigue in rheumatoid arthritis: the role of self-efficacy and problematic social support. British Journal of Rheumatology, 37, 1042-1046.
65. Rocha, A.M., De, S.C., Rocha, G.A., De Melo, F.F., Saraiva, I.S., Clementino, N.C., Marino, M.C. & Queiroz, D.M. (2010) IL1RN VNTR and IL2-330 polymorphic genes are independently associated with chronic immune thrombocytopenia. British Journal of Haematology, 150, 679-684.
66. Rohleder, N., Aringer, M. & Boentert, M. (2012) Role of interleukin-6 in stress, sleep, and fatigue. Annals of the New York Academy of Sciences, 1261, 88-96.
67. Ruggeri, M., Tosetto, A., Palandri, F., Polverelli, N., Mazzucconi, M.G., Santoro, C., Gaidano, G., Lunghi, M., Zaja, F., De Stefano, V., Sartori, R., Fazi, P. & Rodeghiero, F. (2014) Thrombotic risk in patients with primary immune thrombocytopenia is only mildly increased and explained by personal and treatment-related risk factors. Journal of Thrombosis and Haemostasis, 12, 1266-1273.
68. Sarpatwari, A., Watson, S., Erqou, S., Anderson, H., Grainger, J., Higgins, J.P. & Newland, A.C. (2010a) Health-related lifestyle in adults and children with primary immune thrombocytopenia (ITP). British Journal of Haematology, 151, 189-191.
69. Sarpatwari, A., Bennett, D., Logie, J.W., Shukla, A., Beach, K.J., Newland, A.C., Sanderson, S. & Provan, D. (2010b) Thromboembolic events among adult patients with primary immune thrombocytopenia in the United Kingdom General Practice Research Database. Haematologica, 95, 1167-1175.
70. Schmeding, A. & Schneider, M. (2013) Fatigue, health-related quality of life and other patient-reported outcomes in systemic lupus erythematosus. Best Practice & Research. Clinical Rheumatology, 27, 363-375.
71. Schoonen, W.M., Kucera, G., Coalson, J., Li, L., Rutstein, M., Mowat, F., Fryzek, J. & Kaye, J.A. (2009) Epidemiology of immune thrombocytopenic purpura in the General Practice Research Database. British Journal of Haematology, 145, 235-244.
72. Schubert, C., Hong, S., Natarajan, L., Mills, P.J. & Dimsdale, J.E. (2007) The association between fatigue and inflammatory marker levels in cancer patients: a quantitative review. Brain, Behavior, and Immunity, 21, 413-427.
73. Semple, J.W. & Provan, D. (2012) The immunopathogenesis of immune thrombocytopenia: T cells still take center-stage. Current Opinion in Hematology, 19, 357-362.
74. Semple, J.W., Milev, Y., Cosgrave, D., Mody, M., Hornstein, A., Blanchette, V. & Freedman, J. (1996) Differences in serum cytokine levels in acute and chronic autoimmune thrombocytopenic purpura: relationship to platelet phenotype and antiplatelet T-cell reactivity. Blood, 87, 4245-4254.
75. Severinsen, M.T., Engebjerg, M.C., Farkas, D.K., Jensen, A.O., Norgaard, M., Zhao, S. & Sorensen, H.T. (2011) Risk of venous thromboembolism in patients with primary chronic immune thrombocytopenia: a Danish population-based cohort study. British Journal of Haematology, 152, 360-362.
76. Sheng, P., Hou, L., Wang, X., Wang, X., Huang, C., Yu, M., Han, X. & Dong, Y. (2013) Efficacy of modafinil on fatigue and excessive daytime sleepiness associated with neurological disorders: a systematic review and meta-analysis. PLoS ONE, 8, e81802.
77. Signorovitch, J., Brainsky, A. & Grotzinger, K.M. (2011) Validation of the FACIT-fatigue subscale, selected items from FACT-thrombocytopenia, and the SF-36v2 in patients with chronic immune thrombocytopenia. Quality of Life Research, 20, 1737-1744.
78. Snyder, C.F., Mathias, S.D., Cella, D., Isitt, J.J., Wu, A.W. & Young, J. (2008) Health-related quality of life of immune thrombocytopenic purpura patients: results from a web-based survey. Current Medical Research and Opinion, 24, 2767-2776.
79. Spath-Schwalbe, E., Hansen, K., Schmidt, F., Schrezenmeier, H., Marshall, L., Burger, K., Fehm, H.L. & Born, J. (1998) Acute effects of recombinant human interleukin-6 on endocrine and central nervous sleep functions in healthy men. Journal of Clinical Endocrinology and Metabolism, 83, 1573-1579.
80. Stasi, R., Murali, M., Michel, M., Viallard, J.F., Giagounidis, A., Janssens, A., Legg, J., Deuson, R. & Danese, M.D. (2012) Evaluation of bleeding-related episodes in patients with immune thrombocytopenia (ITP) receiving romiplostim or medical standard of care. International Journal of Hematology, 96, 26-33.
81. Swain, M.G. (2000) Fatigue in chronic disease. Clinical Science (London, England: 1979), 99, 1-8.
82. Tarantino, M.D., Fogarty, P., Mayer, B., Vasey, S.Y. & Brainsky, A. (2013) Efficacy of eltrombopag in management of bleeding symptoms associated with chronic immune thrombocytopenia. Blood Coagulation & Fibrinolysis, 24, 284-296.
83. Wang, T., Zhao, H., Ren, H., Guo, J., Xu, M., Yang, R. & Han, Z.C. (2005) Type 1 and type 2 T-cell profiles in idiopathic thrombocytopenic purpura. Haematologica, 90, 914-923.
84. Wang, C.Y., Shi, Y., Min, Y.N., Zhu, X.J., Guo, C.S., Peng, J., Dong, X.Y., Qin, P., Sun, J.Z. & Hou, M. (2011) Decreased IDO activity and increased TTS expression break immune tolerance in patients with immune thrombocytopenia. Journal of Clinical Immunology, 31, 643-649.
85. Wang, Y.M., Jin, B.Z., Ai, F., Duan, C.H., Lu, Y.Z., Dong, T.F. & Fu, Q.L. (2012) The efficacy and safety of melatonin in concurrent chemotherapy or radiotherapy for solid tumors: a meta-analysis of randomized controlled trials. Cancer Chemotherapy and Pharmacology, 69, 1213-1220.
86. Wang, W., Bourgeois, T., Klima, J., Berlan, E.D., Fischer, A.N. & O'Brien, S.H. (2013) Iron deficiency and fatigue in adolescent females with heavy menstrual bleeding. Haemophilia, 19, 225-230.
87. Wood, L.J. & Weymann, K. (2013) Inflammation and neural signaling: etiologic mechanisms of the cancer treatment-related symptom cluster. Current Opinion in Supportive and Palliative Care, 7, 54-59.
88. Xu, S.Q., Wang, C.Y., Zhu, X.J., Dong, X.Y., Shi, Y., Peng, J., Qin, P., Sun, J.Z., Guo, C., Ni, H. & Hou, M. (2012) Decreased indoleamine 2, 3-dioxygenase expression in dendritic cells and role of indoleamine 2, 3-dioxygenase-expressing dendritic cells in immune thrombocytopenia. Annals of Hematology, 91, 1623-1631.
89. Zhan, Y., Zou, S., Hua, F., Li, F., Ji, L., Wang, W., Ye, Y., Sun, L., Chen, H. & Cheng, Y. (2014) High-dose dexamethasone modulates serum cytokine profile in patients with primary immune thrombocytopenia. Immunology Letters, 160, 33-38.
90. Zhao, H., Li, H., Du, W., Zhang, D., Ge, J., Xue, F., Zhou, Z. & Yang, R. (2014) Reduced MIR130A is involved in primary immune thrombocytopenia via targeting TGFB1 and IL18. British Journal of Haematology, 166, 767-773.
91. Zhou, Z., Yang, L., Chen, Z., Chen, X., Guo, Y., Wang, X., Dong, X., Wang, T., Zhang, L., Qiu, Z. & Yang, R. (2007) Health-related quality of life measured by the Short Form 36 in immune thrombocytopenic purpura: a cross-sectional survey in China. European Journal of Haematology, 78, 518-523.
92. Zlott, D.A. & Byrne, M. (2010) Mechanisms by which pharmacologic agents may contribute to fatigue. PM & R: The Journal of Injury, Function, and Rehabilitation, 2, 451-455.